Endocrine therapy against the estrogen receptor (ER) is widely used for the treatment of ER+ breast cancer. Selective estrogen receptor degraders (SERDs) compete directly with estrogen for ER binding and create an unstable protein complex that leads to proteasome-mediated ER protein degradation.